Oral GLP‑1 hits China’s late‑stage bar, US data still pending
Posted by amber464 in Weight Loss & Metabolic - 1 points, 0 comments.
The article reports that Hengrui and Kailera’s oral GLP‑1 agonist, KAI‑7535, passed a late‑stage phase‑3 trial in China and cleared the “late‑stage bar” for regulatory submission, but US data are still a few months away. The trial noted significant weight loss, yet nausea and vomiting were common side effects.
I’m excited that an oral GLP‑1 could improve adherence compared to weekly injections, but the high nausea rate worries me. In my own injection‑based semaglutide protocol, the GI side effects were tolerable with a slow titration, and the weight loss was pretty solid. If the oral version carries the same or worse GI load, it might end up being less effective in real‑world use. I’d love to see head‑to‑head data on the:.
Will the oral GLP‑1 reach the same efficacy and tolerability plateau as semaglutide, or will the side‑effect profile limit its adoption?
Community discussion - research and educational context only. Not medical advice.